26 jan: Villa Joy - dansk konceptbolig med verdensinspiration og potentia..
02 feb: Stort behov for mini-MBA i bestyrelsesuddannelse
28-01-2010 08:02:00

Preliminary Annual Accounts / Fourth Quarter Report 2009

This information is subject of the disclosure requirements acc. to §5-12 vphl

(Norwegian Securities Trading Act)

Rieber & Søn's operating profit (EBIT) in the fourth quarter totalled NOK 185m

(122m), while the figure for the year was NOK 424m (356m). EPS in the fourth

quarter stood at  NOK 1.52  (0.82) and NOK 3.32 (2.46) for the year.

Sales in the fourth quarter came to NOK 1 256m (1 377m), while the figure for

the year was NOK 4 967m (4 997m). Structural effects had a negative effect on

sales, reducing the performance by 1.6% in the fourth quarter, and by 0.6% for

the year. Currency conversion effects reduced sales in the fourth quarter by

4.7% and by 0.4% for the year. Organic growth stood at -2.4% in the fourth

quarter, while the increase for the year was 0.4%.

The gross margin in the fourth quarter rose to 59.2% (57.1%) and to 56.7%

(56,0%) for the year. The Group had good cost control in the fourth quarter and

payroll and operating costs were down 8% at NOK 569m, while the figure for the

year was 1% lower at NOK 2 218m. The EBITDA margin for the fourth quarter was

13,9% (12.1%) and 12.1% (11.2%) for the year. The corresponding figures for

 EBIT margin were 14.7% (8.9%) and 8.5% (7.1%), respectively.

The operating profit in the fourth quarter was positively affected by one-off

effects which contributed NOK 61m. This was the net effect of income of NOK 77m

from the sale of the  Sopps brand and the marine ingredients line in Arna, and

costs of NOK 16m related to the write-down of the production plant for Anja Cake

in Poland and transaction costs for the acquisition of Gellwe which was not

approved by the Polish competition authorities.  The operating profit for the

year was positively affected by one-off effects totalling NOK 32m. The Group's

core activities exclusive one-off items provided EPS of NOK 3.09 for the year,

which was 30% up on 2008.

The return on capital employed was 22.7% (14.1%) in the fourth quarters and

12.8% (10.9%) for the year.

In line with the Group's dividend policy, the Board will ask the AGM to approve

a dividend of NOK 2.00 per share. Together, this represents a 60% increase in

the dividend compared with the previous year and a dividend ratio of 60%.

"Our Future"

"Our Future" is aimed at achieving lasting improvements in results of NOK 400m

in 2012. The extra consumption of resources of a one-time nature in order to

realise these improvements is estimated to cost NOK 125m. The programme is

progressing as planned.

In the fourth quarter, the net effect of improvements in purchasing, production

and marketing under the "Our Future" platform totalled NOK 35m and comprised

positive effects of NOK 44m in the fourth quarter and implementation costs of

NOK 9m. The accumulated total of the positive, lasting effects in the first 12

months was NOK 96m, while implementation costs in the same period came to NOK

47m.

The aim to improve Group profitability was achieved in line with the plans for

2009. Through good cost control and the implementation of efficiency programmes

which provide lasting improvements, a sound basis has been laid for further

growth in profitability.

Bergen, 27 January 2010

Board of Directors of Rieber & Søn ASA

[HUG#1377906]

4Q Quarter Report 2009 : http://hugin.info/121/R/1377906/338577.pdf

4Q Presentation 2009: http://hugin.info/121/R/1377906/338578.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
18 feb
NOVO-B
Når ens hustru har lidt voldsomt under diabetes  og dens bivirkninger tiltagende gennem 25 år, så er..
34
19 feb
 
Jeg tager hatten for dit velbegrunede og fyldestgørende indlæg til debatten. Det kunne mange lære af..
32
21 feb
GEN
Det er altid rart at møde et ungt menneske, der har potentiale til at blive klogere.
26
23 feb
ZEAL
Jeg har tildigere her på EI rapporteret at Soliqua ville blive lanceret i Sydkorea. Nu har Sanofi af..
25
21 feb
GEN
Du bliver da dummere og dummere at høre på 
21
24 feb
NRDF
  Aktieugen er overstået og desværre, men ikke særligt overraskende, viste det sig igen, at det dans..
14
23 feb
ZEAL
Sanofi og  har for et par dage siden oplyst på clinicaltrial.gov at de starter studiet «LixiPark» me..
14
23 feb
GEN
H2 2018 er pakket med nyheder og kliniske data fra daratumumab i solide tumorer er en af de største ..
12
21 feb
TRMD-A
Mange års erfaring i teknisk analyse berettiger mig til at give dig følgende svar:    Torm viser akt..
12
20 feb
 
Helt korrekt. Jeg skiftede job i 2007 og har på denne ene pension fra dette tidspunkt indbetalt 648...
12

Aktier/tendens: William Demant kan tage fokus i grøn åbning

23-02-2018 08:27:52
Der er udsigt til stigninger fredag morgen, når aktiemarkedet herhjemme åbner. Fra åbningen kan William Demant igen tage fokus, efter at selskabet har fået hævet kursmålet af en stribe finanshuse ovenpå torsdagens positive regnskab. I USA lukkede S&P 500 torsdagens handel med et plus på 0,2 pct., mens også Dow Jones lukkede med en gevinst på 0,7 pct. Til gengæld faldt Nasdaq med 0,1 pct. Futures f..

Aktier/middag: Genmab buldrer frem med WDH og ISS som følgesvende

22-02-2018 11:40:57
Biotekselskabet Genmab ligger helt i top i det danske eliteindeks torsdag middag efter at have præsenteret regnskab onsdag aften. Også ISS og William Demant, der begge kom med regnskab for fjerde kvartal torsdag morgen, er med i toppen.Men det er onsdagens regnskab fra Genmab, der trækker den helt store opmærksomhed, efter at biotekselskabet gjorde markedets bekymringer over en mulig skuffende pro..

ISS: Salget vokser mens bundlinjen skrumper

22-02-2018 08:39:00
ISS kan se bundlinjen falde tilbage i 2017 sammenlignet med i 2016, selvom selskabet er vokset på salget.Omsætningen i selskabet voksede til 79.912 mio. kr. i 2017, mens omsætningen udgjorde 78.658 mio. kr. i 2016.Omvendt steg nettoresultatet i 2017 til 2007 mio. kr. mod 2220 mio. kr. året før.Af regnskabet fremgår det, at årsagen til at bundlinjen ikke vokser med toplinjen, blandt andet er ekster..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
25. februar 2018 08:50:23
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: ReleaseBuild_20180222.1 - EUROWEB5 - 2018-02-25 08:50:23 - 2018-02-25 08:50:23 - 1 - Website: OKAY